LIANY — LianBio Share News
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro Cap
U.S. STOCKS ON THE MOVE-Madrigal, Disney, Forward Pharma
U.S. STOCKS ON THE MOVE-Tesla, Madrigal, Qumu, Zymeworks
LianBio rises as Pfizer opts to develop co's RSV therapy
Brief: LianBio Believes Transaction With Pfizer Will Extend Its Cash Runway
Brief: Pfizer Opts In To LianBio Rights To Respiratory Syncytial Virus Therapeutic Candidate Sisunatovir
Brief: LianBio Announces President, Chief Strategy Officer Departure
Brief: Lianbio Files For Mixed Shelf Of Up To $500 Million - SEC Filing
Brief: LianBio Reports Third Quarter 2022 Financial Results And Provides Corporate Update
LianBio gains as dosing begins in eye disorder drug study in China
Brief: Lianbio Doses First Patient In Phase 3 Libra Trial Of Tp-03 In Chinese Patients With Demodex Blepharitis
BridgeBio, LianBio down on discontinuing bile duct cancer drug study
Brief: LianBio Says BridgeBio Pharma Informed Co That Helsinn Healthcare Is Permanently Discontinuing Distribution Of Truseltiq
Brief: Nanobiotix And Lianbio Announce First Patient Enrolled In Asia In Phase 3 Nanoray-312 Trial Evaluating Nbtxr3 For Treatment Of Head And Neck Cancer
Brief: Lianbio Reports Second Quarter 2022 Financial Results And Provides Corporate Update
Brief: Lianbio Completes Enrollment In Pivotal Phase 3 Explorer-Cn Trial Of Mavacamten In Chinese Obstructive Hypertrophic Cardiomyopathy Patients
Brief: LianBio Reports First Quarter 2022 Financial Results And Provides Corporate Update
Brief: LianBio Completes Phase 1 Pharmacokinetic Study Of Mavacamten In Healthy Chinese Volunteers
Brief: LianBio Partner Tarsus Pharmaceuticals Announces Positive Topline Data From Second Pivotal Trial Of TP-03 For The Treatment Of Demodex Blepharitis
Tarsus Pharma prices upsized equity offering after shares tumble